Beryl Drugs Ltd
₹20.19
(-7.17%)
Sat, 07 Mar 2026, 07:09 am
Health Technology
Pharmaceuticals: Other
24.5KBeryl Drugs Return on Equity (ROE) History
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 317 | 185 | 118.44 | 100 | 36.97 | 69.53 | 218.53 | 98.03 | 63.04 | 6.12 | 7.18 | 38.62 | 13.99 | 0 | 8.05 | 19.35 | 18.45 |
| Price to book ratio | 0.87 | 0.84 | 1.70 | 1.51 | 2.34 | 2.93 | 2.92 | 2.48 | 1.25 | 0.91 | 0.56 | 0.24 | 0.42 | 0.73 | 0.76 | 1.67 | 1.12 |
| Price to sales ratio | 0.69 | 0.69 | 1.31 | 0.95 | 1 | 1.29 | 1.42 | 1.26 | 0.67 | 0.40 | 0.33 | 0.14 | 0.24 | 0.37 | 0.23 | 0.56 | 0.51 |
| Price to cash flow ratio | 22.14 | 15.92 | 126.60 | 14.28 | 22.50 | 0 | 71.31 | 0 | 25.55 | 0 | 1.21 | 0 | 0 | 0 | 3.15 | 41.70 | 5.07 |
| Enterprise value | 56.16M | 54.25M | 106.81M | 94.57M | 144.99M | 199.82M | 197.45M | 174.74M | 84.33M | 74.23M | 73.85M | 66.9M | 78.22M | 99.22M | 101.35M | 197.46M | 138.68M |
| Enterprise value to EBITDA ratio | 12.29 | 10.61 | 29.93 | 19.88 | 15.63 | 25.97 | 26.78 | 33.91 | 17.02 | 7.02 | 7.22 | 7.39 | 5.39 | 23.83 | 5.16 | 8.65 | 11.25 |
| Debt to equity ratio | 0.17 | 0.14 | 0.18 | 0.16 | 0.15 | 0.24 | 0.27 | 0.26 | 0.29 | 0.22 | 0.43 | 0.69 | 0.65 | 0.73 | 0.56 | 0.57 | 0.43 |
| Return on equity % | 0 | 0.43 | 1.47 | 1.56 | 6.64 | 4.29 | 1.32 | 2.55 | -7.16 | 14.80 | 8.32 | 0.63 | 3.08 | -8.66 | 9.97 | 9.05 | 6.28 |
Beryl Drugs Ltd Return on Equity
The Beryl Drugs Ltd Return on Equity is a key financial metric used by investors to evaluate Beryl Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Beryl Drugs Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Beryl Drugs Ltd (NSE: , BSE: 524606) is currently trading at ₹20.19, with a market capitalization of ₹102.4M. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Beryl Drugs Ltd Return on Equity is essential for fundamental analysis.
Beryl Drugs Ltd Return on Equity Current Value
The current Beryl Drugs Ltd Return on Equity stands at 6.28.
The Beryl Drugs Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Beryl Drugs Ltd Return on Equity Historical Trend
The Beryl Drugs Ltd Return on Equity has shown the following historical trend:
- 2024: 6.28
- 2023: 9.05
- 2022: 9.97
- 2021: -8.66
- 2020: 3.08
The decline in Beryl Drugs Ltd Return on Equity indicates improving financial efficiency or better earnings growth.
What Beryl Drugs Ltd Return on Equity Indicates for Investors
The Beryl Drugs Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Beryl Drugs Ltd Return on Equity Analysis Summary
The Beryl Drugs Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Beryl Drugs Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Beryl Drugs Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800